Bright Minds Biosciences Inc. DRUG
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.56M | 1.63M | 776.60K | 543.90K | 427.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 187.20K | -186.40K |
| Total Operating Expenses | 8.24M | 11.14M | 4.84M | 4.20M | 2.19M |
| Operating Income | -8.24M | -11.14M | -4.84M | -4.20M | -2.19M |
| Income Before Tax | -1.73M | -7.62M | -5.43M | -2.97M | -3.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.73M | -7.62M | -5.43M | -2.97M | -3.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.73M | -7.62M | -5.43M | -2.97M | -3.79M |
| EBIT | -8.24M | -11.14M | -4.84M | -4.20M | -2.19M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.18 | -0.80 | -0.70 | -0.41 | -0.53 |
| Normalized Basic EPS | -0.11 | -0.50 | -0.44 | -0.26 | -0.33 |
| EPS Diluted | -0.18 | -0.80 | -0.70 | -0.41 | -0.53 |
| Normalized Diluted EPS | -0.11 | -0.50 | -0.44 | -0.26 | -0.33 |
| Average Basic Shares Outstanding | 9.83M | 9.59M | 7.76M | 7.23M | 7.08M |
| Average Diluted Shares Outstanding | 9.83M | 9.59M | 7.76M | 7.23M | 7.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |